Welcome to our dedicated page for Clear Secure SEC filings (Ticker: YOU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Every line of Clear Secure’s SEC narrative begins with biometrics. Whether it’s detailing how CLEAR Plus converts airport wait time into subscription revenue or outlining the cost to enroll new TSA PreCheck members, investors want the facts behind the kiosks they see at JFK. Our page gathers those facts in one spot: from the latest Clear Secure insider trading Form 4 transactions to the Clear Secure quarterly earnings report 10-Q filing, all delivered the moment they hit EDGAR.
Wondering how hardware amortization shows up in cash flow or how biometric privacy liabilities are disclosed? Click any document and you’ll find Clear Secure Form 4 insider transactions real-time, Clear Secure SEC filings explained simply with AI-powered summaries, and Clear Secure earnings report filing analysis that translates technical accounting into plain English. Our platform links each filing type to the question it answers�10-Ks for membership churn, 8-Ks for new airport contracts, proxies for director pay—so you never have to hunt through footnotes.
Start by understanding Clear Secure SEC documents with AI, then drill into the Clear Secure executive stock transactions Form 4 feed, review a Clear Secure annual report 10-K simplified, or compare board pay in the Clear Secure proxy statement executive compensation table. Need to see how a sudden venue partnership impacts guidance? The Clear Secure 8-K material events explained section is already annotated. With real-time alerts, expert commentary, and a full archive, our coverage turns dense filings into actionable insight—faster than you can clear security.
Prospect Capital Corporation (PSEC) has filed a preliminary pricing supplement for three new unsecured senior notes under its InterNotes® program:
- 7.500% Notes due 2028 � CUSIP 74348GWC0
- 7.750% Notes due 2030 � CUSIP 74348GWD8
- 8.000% Notes due 2032 � CUSIP 74348GWE6
All issues are offered in $1,000 denominations, pay semi-annual interest beginning 15 Jan 2026 and are callable at par on or after 15 Jan 2026. A Survivor’s Option allows early repayment upon the holder’s death, subject to annual caps.
Pricing details (pre-fee): 2028 Notes sold at 101.125%, 2030 at 101.700% and 2032 at 101.950%, implying modest premiums to face value. Gross concessions range from 1.125% to 1.950%.
Strategic context
- Liability management: In Apr-Jun 2025 PSEC fully retired its $342.9 m 3.706% Notes due 2026 via tender (99% plus accrued) and subsequent redemption, eliminating a nearer-term maturity.
- Portfolio re-positioning: Sold subordinated structured notes with $324.6 m cost basis for $74.6 m cash; provided $39.6 m of new first-lien financing to National Property REIT Corp., received $19 m of repayments, and closed the acquisition of QC Holdings with a $55 m senior loan plus $22.3 m equity.
Capital structure impact
- New notes will rank pari passu with existing unsecured debt and be structurally subordinated to $0.7 bn of secured borrowings (Feb 2023) under the credit facility.
- Coupons of 7.5-8.0% exceed the retired 3.706% issue, indicating materially higher future interest expense but extend the weighted-average maturity to 2028-2032.
Key dates: Trade 14 Jul 2025, settle 17 Jul 2025; interest accrues from settlement.
Risks highlighted include rising leverage, higher funding costs, covenant limitations under the revolver, potential rating pressure, and market volatility in SOFR-linked issuances. No earnings metrics were provided in this filing.
Inhibikase Therapeutics, Inc. (IKT) has filed an amended Form 4 (Form 4/A) for Chief Executive Officer and Director Mark T. Iwicki. The sole purpose of the amendment is to correct two data points that were misstated in the original Form 4 filed on 25 Feb 2025: (i) the exercise price of a stock-option award and (ii) its expiration date.
Key terms of the option grant (originally awarded 21 Feb 2025):
- Derivative security: Non-qualified stock option to purchase 602,346 shares of common stock.
- Corrected exercise price: $2.97 per share.
- Corrected expiration date: 21 Feb 2035 (10-year term).
- Vesting schedule: 48 substantially equal monthly installments beginning 21 Mar 2025, contingent on continued employment.
- Ownership status: Shares are held directly by the reporting person.
The filing does not report new purchases or sales of shares; it is an administrative correction. Nevertheless, the option grant, if fully exercised, would result in issuance of up to 602,346 new shares, creating a modest potential dilution for existing shareholders. Because the option vests over four years, dilution would be gradual and contingent on share-price appreciation above $2.97.
Investor takeaways: (1) Management has rectified an earlier clerical error, demonstrating regulatory compliance; (2) the CEO’s long-term incentive package now has confirmed terms, aligning his interests with shareholders; (3) no immediate cash outflow or revenue impact is associated with the amendment.
Clear Secure, Inc. (NYSE: YOU) filed a Form 144 indicating a proposed insider sale of 3,000 Class A shares valued at roughly $83,250. The shares, representing less than 0.01 % of the company’s 92.27 million shares outstanding, were originally acquired through restricted-stock vesting on 30 June 2021 and are slated to be sold through Fidelity Brokerage on or about 1 July 2025. No other sales by the filer have occurred in the past three months. Form 144 is a notice only—execution is not guaranteed—and the signer affirms no undisclosed material information. Given the de-minimis size, the transaction is unlikely to have a material impact on share price or corporate governance.